Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- čipová analýza proteinů MeSH
- čipová analýza tkání MeSH
- imunohistochemie MeSH
- jaderné proteiny genetika metabolismus MeSH
- lidé MeSH
- nádory plic metabolismus patologie MeSH
- nemalobuněčný karcinom plic metabolismus patologie MeSH
- PRC1 MeSH
- prognóza MeSH
- protoonkogenní proteiny genetika metabolismus MeSH
- represorové proteiny genetika metabolismus MeSH
- staging nádorů MeSH
- stanovení celkové genové exprese MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- BMI1 protein, human MeSH Prohlížeč
- jaderné proteiny MeSH
- PRC1 MeSH
- protoonkogenní proteiny MeSH
- represorové proteiny MeSH
PURPOSE: Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes. METHODS: Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS. RESULTS: Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10(-6)) and stage IV (P = 10(-5)) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased DFS at stage I and II patients who did not express Bmi-1 when compared to their Bmi-1 positive counterparts (P = 0.05). CONCLUSIONS: Our results suggest that Bmi-1 is significantly associated with progression of NSCLC and might serve as a prognostic marker of adverse disease outcome.
Citace poskytuje Crossref.org
Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression